Key facts
- This page summarizes Matthew W. Strobeck's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2021, 15:01.
Matthew W. Strobeck - 30 Sep 2021 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)
- Reporting relationship
- Director
- Issuer ticker
- AXDX
- Reported as of
- 30 Sep 2021
- Net transaction value
- +$149,998
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 15:01:08 UTC
- Prior SEC filing
- 01 Jul 2021
- Next SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Reichling, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Matthew W. Strobeck filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 10 Dec 2021.
Change
- Previous filing in this sequence was filed on 01 Jul 2021.
- Current net transaction value: +$149,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXDX
transaction
Common Stock
Award
- Transaction value
- $149,998
- Shares
- +19,531
- Change %
- +10%
- Price
- $7.68
- Shares after
- 206,828
- Date
- 30 Sep 2021
- Ownership
- By Birchview Fund, LLC
- Footnotes
- F1, F2
AXDX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,025,560
- Date
- 30 Sep 2021
- Ownership
- Direct
AXDX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 30 Sep 2021
- Ownership
- As UGMA Custodian for minor children
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the third and final tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The third and final tranche of the offering closed on September 30, 2021.
Footnote F2
The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.